A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian CancerFarasat Kazmi, Sarah P. Blagden, Chat Gnanaranjan et al.|Clinical Cancer Research|2021Cited by 10
Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumorsEssam Ghazaly, Sarah P. Blagden, Chat Gnanaranjan et al.|Annals of Oncology|2017Cited by 4
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignanciesSarah P. Blagden, T.R. Jeffry Evans, Essam Ghazaly et al.|Annals of Oncology|2018Cited by 2